Clinical trials: Glioma Tumor Recurrence
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
This study is being done to evaluate the toxicity and safety of carboplatin administered by convection enhanced delivery into the tumor in patients with high grade glial neoplasms.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Recurrent Adult Brain Tumor
- Trial name
- NCT01644955
- Testing
- carboplatin, Surgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- James Elder
Brain and Central Nervous System Tumors, Metastatic Cancer
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
RATIONALE: Photodynamic therapy uses light and photosensitizing drugs to kill tumor cells and may be an effective treatment for refractory brain tumors.
- Trial name
- NCT00002647
- Testing
- verteporfin, conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
Brain and Central Nervous System Tumors
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT01390571
- Testing
- olaparib, temozolomide, gene expression analysis
- Where
- 7 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Cancer Research UK
Recurrent Glioblastoma
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma
- Trial name
- NCT04717999
- Testing
- NKG2D CAR-T
- Volunteers
- 20 people
- Sponsor
- UWELL Biopharma
Malignant Glioma, Brain Tumor, Recurrent
D2C7 for Adult Patients With Recurrent Malignant Glioma
This is a Phase I study to determine the maximum tolerated dose (MTD) and/or recommended phase II dose of D2C7-IT (D2C7 Immunotoxin) when delivered intratumorally by convection-enhanced delivery (CED) to recurrent World Health…
- Trial name
- NCT02303678
- Testing
- D2C7-IT
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Darell Bigner
Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma
Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
This phase I trial studies the side effects and best dose of savolitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm
- Trial name
- NCT03598244
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib
- Where
- 12 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Neoadjuvant Therapy, Carilizumab
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
GBM is the most common intracranial tumor in adults, accounting for about 40% of all primary intracranial tumors.Although surgery, radiotherapy and chemotherapy have been used, the prognosis of glioma patients is still very poor.
- Conditions
- Neoadjuvant Therapy, Carilizumab, Apatinib, Recurrent High-Grade Glioma
- Trial name
- NCT04588987
- Testing
- PD-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Medulloblastoma, Childhood, Medulloblastoma Recurrent
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
This is a multi center, Phase I, Phase II and surgical study of the CX-4945 drug (silmitasertib sodium) for patients with recurrent SHH (Sonic Hedgehog) medulloblastoma
- Conditions
- Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
- Trial name
- NCT03904862
- Testing
- CX 4945
- Where
- 12 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pediatric Brain Tumor Consortium
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
This phase I trial is studying the side effects and best dose of ABT-888 when given in combination with temozolomide in treating young patients with recurrent or refractory CNS tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00946335
- Testing
- veliparib, temozolomide, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
- Trial name
- NCT01106508
- Testing
- LEQ506
- Where
- 5 sites in United States, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent or Progressive Glioblastoma
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
This clinical trial is a prospective study of radiosurgery treatment for progressive GBM to test 1)the efficacy of radiosurgery for recurrent/progressive GBM compared to chemotherapy , and 2) the role of diffusion-weighted image…
- Trial name
- NCT05718466
- Testing
- Bevacizumab, Chemotherapy, Fractionated radiosurgery
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Henry Ford Health System
Brain and Central Nervous System Tumors
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent…
- Trial name
- NCT00002986
- Testing
- carmustine, topotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Neuroblastoma
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00503724
- Testing
- enzastaurin hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Mixed Gliomas
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
RATIONALE: Current therapies for adults with recurrent or refractory mixed gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the…
- Trial name
- NCT00003473
- Testing
- Atengenal, Astugenal
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Burzynski Research Institute
Recurrent IDH, Mutant High Grade Glioma
Olaparib in Recurrent IDH-mutant Glioma
Recent data demonstrate that in IDH-mutant gliomas, 2 hydroxy-glutarate production induces a homologous recombination defect that renders tumor cells exquisitely sensitive to poly(adenosine 5'-diphosphate-ribose) polymerase…
- Trial name
- OLAGLI (NCT03561870)
- Testing
- Olaparib 150 MG
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Hospices Civils de Lyon
Recurrent High-grade Glioma
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
Researchers will investigate the ability of Xevinapant to cross the blood-brain barrier and exert anti-tumor effects on rHGG through activation of apoptosis.
- Trial name
- NCT06463184
- Testing
- Xevinapant
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Medulloblastoma, Neuroectodermal Tumor
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Immunotherapy is a specific approach to treating cancer that has shown promise in adult patients for the treatment of melanoma, malignant brain tumors, and other cancers.
- Trial name
- Re-MATCH (NCT01326104)
- Testing
- TTRNA-xALT, TTRNA-DCs
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Florida
Primary Brain Tumor, Brain Tumor, Recurrent
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
The purpose of this research study is to determine if fluoxetine increases lysosomal stress in patients with recurrent IDHwt glioma by evaluating LAMP1 expression in tumor samples obtained pre-resection via biopsy and during…
- Trial name
- NCT05634707
- Testing
- Fluoxetine, Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Gliosarcoma
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
The primary objective of this study is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of dasatinib when combined with protracted, daily temozolomide (TMZ).
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00734864
- Testing
- enzyme-inducing anti-epileptic drugs
- Where
- United States
- Sponsor
- Annick Desjardins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.